Shopping Cart 0
Cart Subtotal
AED 0

Eisai Co Ltd (4523) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Eisai Co Ltd, Medical Equipment, Deal Details 11

Partnerships 11

Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11

Biocare Medical Enters into Licensing Agreement with Morphotek 12

Eisai Enters into Co-Development Agreement with MAMORIO 13

Cancer Genetics Partners with H3 Biomedicine 14

Eisai Enters into Agreement with Sysmex 15

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18

Acquisition 19

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19

Robert Bosch Completes Acquisiton Of Eisai Machinery 20

Eisai Co Ltd-Key Competitors 22

Eisai Co Ltd-Key Employees 23

Eisai Co Ltd-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Joint Venture 29

Recent Developments 30

Strategy And Business Planning 30

Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 30

Corporate Communications 31

Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 31

Aug 27, 2018: Stephen Davies appointed Vice President, Eisai strategic information systems at Eisai 32

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 33

Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 34

Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 35

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 36

Nov 20, 2017: Eisai Receives IT Business Award For Medication Administration Support Device e-OKUSURI-SAN Equipped With Functions To Support Looking After Patients 37

Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 38

May 10, 2017: Eisai: Proposed Changes in Representative Officers 39

Government and Public Interest 40

Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 40

Product News 41

Jan 12, 2017: Eisai To Launch Medication Administration Support Device e-OKUSURI-SAN 41

Other Significant Developments 42

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 42

Sep 12, 2017: Eisai and MAMORIO to Jointly Launch Me-MeMAMORIO Tracking Tool to Support People With Dementia and Seniors Going Out 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Eisai Co Ltd, Medical Equipment, Key Facts, 2018 2

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Deals By Market, 2012 to YTD 2018 9

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11

Biocare Medical Enters into Licensing Agreement with Morphotek 12

Eisai Enters into Co-Development Agreement with MAMORIO 13

Cancer Genetics Partners with H3 Biomedicine 14

Eisai Enters into Agreement with Sysmex 15

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19

Robert Bosch Completes Acquisiton Of Eisai Machinery 20

Eisai Co Ltd, Key Competitors 22

Eisai Co Ltd, Key Employees 23

Eisai Co Ltd, Subsidiaries 26

Eisai Co Ltd, Joint Venture 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Eisai Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Eisai Co Ltd, Medical Equipment, Deal Details 11

Partnerships 11

Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11

Biocare Medical Enters into Licensing Agreement with Morphotek 12

Eisai Enters into Co-Development Agreement with MAMORIO 13

Cancer Genetics Partners with H3 Biomedicine 14

Eisai Enters into Agreement with Sysmex 15

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18

Acquisition 19

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19

Robert Bosch Completes Acquisiton Of Eisai Machinery 20

Eisai Co Ltd-Key Competitors 22

Eisai Co Ltd-Key Employees 23

Eisai Co Ltd-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Joint Venture 29

Recent Developments 30

Strategy And Business Planning 30

Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 30

Corporate Communications 31

Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 31

Aug 27, 2018: Stephen Davies appointed Vice President, Eisai strategic information systems at Eisai 32

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 33

Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 34

Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 35

Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 36

Nov 20, 2017: Eisai Receives IT Business Award For Medication Administration Support Device e-OKUSURI-SAN Equipped With Functions To Support Looking After Patients 37

Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 38

May 10, 2017: Eisai: Proposed Changes in Representative Officers 39

Government and Public Interest 40

Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 40

Product News 41

Jan 12, 2017: Eisai To Launch Medication Administration Support Device e-OKUSURI-SAN 41

Other Significant Developments 42

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 42

Sep 12, 2017: Eisai and MAMORIO to Jointly Launch Me-MeMAMORIO Tracking Tool to Support People With Dementia and Seniors Going Out 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Eisai Co Ltd, Medical Equipment, Key Facts, 2018 2

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Eisai Co Ltd, Deals By Market, 2012 to YTD 2018 9

Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11

Biocare Medical Enters into Licensing Agreement with Morphotek 12

Eisai Enters into Co-Development Agreement with MAMORIO 13

Cancer Genetics Partners with H3 Biomedicine 14

Eisai Enters into Agreement with Sysmex 15

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19

Robert Bosch Completes Acquisiton Of Eisai Machinery 20

Eisai Co Ltd, Key Competitors 22

Eisai Co Ltd, Key Employees 23

Eisai Co Ltd, Subsidiaries 26

Eisai Co Ltd, Joint Venture 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Eisai Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.